Advancing Gene-Targeted Therapies for Central Nervous System Disorders Proceedings of a Workshop (2019) / Chapter Skim
Currently Skimming:
Appendix C: Registered Attendees
Appendix C: Registered Attendees
Pages 73-80
The Chapter Skim interface presents what we've algorithmically identified as the most significant single chunk of text within every page in the chapter.
Select key terms on the right to highlight them within pages of the chapter.
From page 73... ...
Appendix C Registered Attendees Asa Abeliovich Reem Aljuhani Prevail Therapeutics Georgetown University Amy Adams Kathleen Anderson National Institute of Neurological National Institute of Mental Health Disorders and Stroke Megan Anderson Brooks Andrew Adams CRD Associates Eli Lilly and Company Patrick Antonellis Julie Adams Eli Lilly and Company PPD Biotech Irina Antonijevic Diaa Ahmed Wave Life Sciences Utrecht University Mona Ashiya Zeshan Ahmed OrbiMed Eli Lilly and Company Nazem Atassi Effie Albanis Sanofi Genzyme Neurogene, Inc. Shelli Avenevoli Robert Alexander National Institute of Mental Health Takeda Pharmaceuticals 73
|
From page 74... ...
Carsten Bonnemann National Institute of Neurological Lisa Chong Disorders and Stroke Science Magazine Lizbet Boroughs Stephanie Ciarlone Association of American Universities PTC Therapeutics Chris Boshoff Timothy Coetzee National Institute of Neurological National Multiple Sclerosis Society Disorders and Stroke Jonathan Cohen Linda Brady Princeton University National Institute of Mental Health Renee Corcoran David Bredt Axovant Janssen R&D Ronald Crystal Katja Brose Weill Cornell Medicine Chan Zuckerberg Initiative
|
From page 75... ...
Bureau of Labor Statistics Kevin Hibbert Keith Fargo Neurogene, Inc. Alzheimer's Association Ramona Hicks Boris Feldman One Mind Rite Aid Pharmacy Mi Hillefors Boris Feldman National Institute of Mental Health Wilson Sonsini Goodrich & Rosati Richard Hodes E'Lissa Flores National Institute on Aging Milken Institute Stuart Hoffman Allyson Gage Department of Veterans Affairs Cohen Veterans Bioscience
|
From page 76... ...
76 ADVANCING GENE-TARGETED THERAPIES FOR CNS DISORDERS Bruce Hope Sooja Kim National Institute on Drug Abuse National Institutes of Health Nina Hsu Rune Kjeken National Institutes of Health Norwegian Medicines Agency Steven Hyman Kelly Knopp The Broad Institute Eli Lilly and Company Yoshimasa Ito Ying-Yee Kong Eisai Department of Veterans Affairs Marcus Jackson Jeffrey Kordower Queens College, The City University Rush University Medical Center of New York Paul Korner Anjana Jain Axovant Gene Therapies Food and Drug Administration Walter Koroshetz Frances Jensen National Institute of Neurological University of Pennsylvania Health Disorders and Stroke System Ana Kostic Sophia Jeon Seaver Autism Center for Research National Institute of Neurological & Treatment, Icahn School of Disorders and Stroke Medicine at Mount Sinai Jeymohan Joseph Robert Kotin National Institute of Mental Health Generation Bio University of Massachusetts Akiva Katz Medical School University of Illinois College of Medicine Rockford John Krystal Yale University School of Medicine Petra Kaufmann AveXis Lina Kubli Department of Veterans Affairs Anastasia Khvorova RNA Therapeutics Institute Story Landis University of Massachusetts National Institute of Neurological Medical School Disorders and Stroke
|
From page 77... ...
David Litwack Yi Mo Prevail Therapeutics Axovant Sciences Laura Mamounas Jill Morris National Institute of Neurological National Institute of Neurological Disorders and Stroke Disorders and Stroke Glenn Mannheim Jennifer Moser Food and Drug Administration Department of Veterans Affairs Janet Marchibroda Mattia Mroso Bockorny Group American Association for the Advancement of Science Peter Marks Food and Drug Administration Avindra Nath National Institute of Neurological Christine Marx Disorders and Stroke Duke University School of Medicine Rosie Stovell O'Donnell Encoded Therapeutics
|
From page 78... ...
Jude Samulski Department of Veterans Affairs University of North Carolina at Chapel Hill
|
From page 79... ...
APPENDIX C 79 Eric Schaeffer Edmund Talley Janssen R&D National Institute of Neurological Disorders and Stroke Tamera Schneider National Science Foundation Amir Tamiz National Institute of Neurological Nina Schor Disorders and Stroke National Institute of Neurological Disorders and Stroke Hiroaki Tani Eli Lilly and Company Kelly Servick Science Magazine Anderson Umah Neolife Health International Douglas Sheeley National Institute of Dental and Akshay Vaishnaw Craniofacial Research Alnylam Chun-Pyn Shen Rita Valentino EMD Serono, Inc. National Institute on Drug Abuse Lamya Shihabuddin Rosaire Verna Sanofi Georgetown University John Sims Christina Vert Eli Lilly and Company National Institute of Neurological Disorders and Stroke Anirudh Srirangam Roivant Sciences Jeannie Visootsak Neurogene Michael Steinmetz National Eye Institute Bhavya Voleti Merck Junghae Suh Rice University Nora Volkow National Institute on Drug Abuse James Sweet Wilson Sonsini Goodrich & Rosati Hao Wang Takeda Pharmaceuticals Holly Tabor Stanford University School of Shiyu Wang Medicine Dicerna Pharmaceuticals
|
From page 80... ...
80 ADVANCING GENE-TARGETED THERAPIES FOR CNS DISORDERS Jackie Ward Clinton Wright National Institute of Neurological National Institute of Neurological Disorders and Stroke Disorders and Stroke Andrew Welchman Rui Wu Wellcome Trust MeiraGTx Pamella Williams Winifred Wu Health Services Authority Strategic Regulatory Partners, LLC Doug Williamson Yining Xie Lundbeck National Institutes of Health Rachel Witten Li-chiung Yang Food and Drug Administration Unaffiliated
|
Key Terms
This material may be derived from roughly machine-read images, and so is provided only to facilitate research.
More
information on Chapter Skim is available.